Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2018

View Archived Issues

LLY-283 demonstrates promising antitumor activity in vitro and in vivo

Combined approaches used to obtain selective Nav1.7 inhibitors

Study yields surprise findings on costimulatory domains

Theralase seeks Canadian clearances for phase II study of TLD-1433 in bladder cancer

DSMB reaffirms its recommendation to continue the phase II XanADu study

Xintela announced progress in its development programs

VBX-100 demonstrates positive safety data in vitro

Genentech describes discovery of a highly potent SERD for treatment of cancer

NEU-4438: an advanced lapatinib-derived lead compound against trypanosomiasis

Cathepsin S inhibitors discovered at Astellas

Sichuan University describes inhibitors of mutant FLT-3 kinase

Ancureall Biomedical Technology divulges histone-lysine N-methyltransferase EZH2 inhibitors

Kyoto University, Astellas present CDK8/CDK19 dual inhibitors

Korea Research Institute of Chemical Technology, Dong-Wha Pharmaceuticals describe BRD4 inhibitors

Multitarget kinase inhibitors disclosed by Bukwang Pharmaceutical

Merck & Co. patents HIV integrase inhibitors

Jupiter Orphan Therapeutics announces favorable Jotrol preclinical data

UP Therapeutics identifies proteasome inhibitors

FDA approves Oxervate for neurotrophic keratitis

Nuevolution reveals lead discovery program targeting inhibition of IL-17A using small molecules

Impel initiates phase III study of INP-104 for migraine

AbbVie reports topline results from phase III extension study with elagolix for uterine fibroids

Phase III SOLAR-1 study of BYL-719 in breast cancer meets PFS primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...